Drug Trial Radar · NCT04737213
SGM-101 in Colorectal Lung Metastases
Last checked: Nov 19, 2026Latest source record: Feb 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
10
Planned (sponsor's estimate)
Start
Nov 1, 2020
Primary completion
Nov 1, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- Leiden University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Erasmus Medical Center; Surgimab
- First posted
- Feb 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Near-infrared fluorescence-guided oncologic surgery (FGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness. SGM-101 already proven to be safe and valuable in colorectal cancer. This study aims to prove feasibility for colorectal lung metastases.
Conditions
- Colorectal Cancer
- Metastatic Colon Cancer
Interventions
SGM-101Drug
Fluorescence guided surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ability of SGM-101 and a near-infrared camera system to detect colorectal lung metastases.Time frame: peroperative
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Erasmus Medical Center
Rotterdam, Netherlands · Not yet recruiting
Leiden University Medical Center
Leiden, South Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.